Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel
View original at finance.yahoo.comTop Stock Reports for Berkshire Hathaway, AstraZeneca & Intel Tuesday, December 30, 2025 The Zacks Research Daily presents the best research output of our analyst team…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Growing U.S.-China geopolitical tensions are likely to impact Intel's margins
80% confidenceIntel Core Ultra features 2.5 times better power efficiency than the previous generation
80% confidenceABM's ELEVATE multi-year comprehensive strategic plan is expected to accelerate the company's top-line growth and reinforce profitability
80% confidenceSolid traction of Middleby's Food Processing Equipment Group segment, fueled by increased demand for protein and bakery products, will continue to lend momentum
80% confidenceKingsway Financial EBITDA run-rate is estimated to be $20.5 million to $22.5 million
80% confidenceBath & Body Works faces soft demand, heavier promotions, tariff-driven margin pressure, lowered guidance, and rising competition
80% confidenceBK Technologies is positioned to expand its share in the $2.3 billion U.S. LMR market
80% confidenceDatadog is benefitting from expanding customer base driven by increased adoption of its cloud-based monitoring and analytics platform
80% confidenceUSA Compression Partners' strong presence in fast-growing basins positions it well to capture additional demand as production activity continues to rise
80% confidenceContinued insurance business growth fuels an increase in float, drives earnings and generates maximum return on equity at Berkshire Hathaway
80% confidenceStarbucks is grappling with elevated coffee costs, tariffs and soft traffic trends
80% confidenceAstraZeneca's key drugs like Lynparza, Tagrisso, Imfinzi, Farxiga and Fasenra should keep driving revenues
80% confidenceStrong adoption of BKR 9000 and 5000 has driven double-digit revenue growth and eight consecutive profitable quarters for BK Technologies
80% confidenceBerkshire Hathaway is one of the largest property and casualty insurance companies with numerous diverse business activities
80% confidenceGitLab benefits from expanding its product portfolio and strong enterprise demand for its AI-native DevSecOps platform
80% confidenceAAR is benefiting from rising air travel demand and increased defense spending
80% confidenceNIO appears poised for a robust growth phase, fueled by an expanding vehicle portfolio
80% confidenceJAKKS Pacific's performance is being hurt by volatile tariffs that raised product costs and pressured demand, with retailer order delays and pushed-back set dates as concerns
80% confidenceKingsway Financial completed six acquisition deals year to date versus three to five guided
80% confidenceIntensifying competition from AMD in the commercial PC market is hindering Intel's growth
80% confidenceHigh operating expenses are likely to weigh on NIO's margins
80% confidenceAstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period
80% confidenceIncreasing complex AI workloads in data centers are driving demand for Intel Xeon 6 processors
80% confidencePediatrix Medical revenues are driven by stable patient volumes and an enhanced telehealth services suite
80% confidenceCullen/Frost's branch expansion efforts in the Texas region will drive deposit and loan growth
80% confidenceExposure to catastrophe loss induces earnings volatility and affects underwriting results at Berkshire Hathaway
80% confidenceCooper Companies' growth is fueled by premium lens migration and first-mover advantage in myopia management, offsetting weakness in APAC region and fertility segment
80% confidenceImpact of Part D redesign on U.S. oncology sales and biosimilar/generic erosion have been key top-line headwinds for AstraZeneca in 2025
80% confidence